Skip to main content

Table 1 Patients and treatments characteristics

From: Neutrophil count is associated with survival in localized prostate cancer

Age (y)   
  Median (range) 67 44-87
PSA at diagnosis (ng/mL)  
  Median (range) 8.1 0.2-132
AJCC tumor classification (N, %)
  T1 1126 64 %
  T2 627 32 %
  T3 80 4 %
Gleason score (N; %)  
  ≤6 930 53 %
  7 752 42 %
  ≥8 90 5 %
NCCN risk groups (N; %)  
  Low 748 42 %
  Intermediate 855 48 %
  High 169 10 %
PPC (N, %)   
  <34 % 883 50 %
  ≥34 % 883 50 %
CAPRA score>  
  0-2 759 43 %
  3-5 811 46 %
  6-10 194 11 %
BMI   
  Median (range) 28.2 13.9–52.5
Diabetes (N; %)>  
  Yes 272 15 %
  No 1500 85 %
Statin use (N; %)>  
  Yes 762 43 %
  No 1010 57 %
CVD (N; %)  
  Yes 629 35 %
  No 1143 65 %
HTN (N; %)   
  Yes 815 46 %
  No 957 54 %
Lymphocytes (103 cells/μL)  
  Median (range) 1.7 0.4–16
Neutrophils (103 cells/μL)   
  Median (range) 4.5 0.9–12
NLR   
  Median (range) 3.0 0.1–18.4
Treatment characteristics
Radiotherapy   
  HDR brachytherapy 52 3 %
  LDR brachytherapy 901 51 %
  EBRT 815 46 %
Androgen deprivation>  
  Non 1551 87 %
  Yes 221 13 %
  1. PSA = prostate-specific antigen; AJCC = American Joint Committee on Cancer; NCCN = National Comprehensive Cancer Network; PPC = percentage of positive cores at prostate biopsies; CAPRA = Cancer of the Prostate Risk Assessment score, BMI = body mass index; CVD = cardiovascular disease; HTN = hypertension. >HDR = High dose rate; LDR = Low dose rate. Lymphocytes, neutrophils and NLR were available for 950 patients; BMI was available for 544 patients; data was available for entire cohort (1772 patients) for all the other factors.